Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00218569 · ClinicalTrials.gov registry record · Phase 2

Combined Treatment for Cocaine-Alcohol Dependence - 1

A Phase 2 study of Alcohol Dependence and Cocaine Dependence, sponsored by The University of Texas Health Science Center, Houston.

Completed
Registry status
Phase 2
Development phase
87
Enrollment target
1
Study location

NCT00218569: Completed Phase 2 study of Alcohol Dependence and Cocaine Dependence, sponsored by The University of Texas Health Science Center, Houston.

NCT00218569 is a Phase 2 study of Alcohol Dependence and Cocaine Dependence that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 87 participants, below the 312-participant average among 43 other Alcohol Dependence trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00218569, a Phase 2 study of Alcohol Dependence and Cocaine Dependence, has completed, sponsored by The University of Texas Health Science Center, Houston.

COMPLETED
Registry status
Phase 2
Development phase
87 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine whether Naltrexone and cognitive behavioral therapy can be helpful in patients who want to stop using cocaine and alcohol.

Interventions

  • DRUG Placebo
  • DRUG Naltrexone

Study Locations (1)

Texas

  • University of Texas Health Sci Cntr Houston - Houston

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2003-04
Est. Completion 2007-12
Phase Phase 2

What the finished NCT00218569 record still lists

NCT00218569 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 312-participant average among 43 other Alcohol Dependence trials with a reported enrollment target (72% lower).

The record links to 2 conditions, with Alcohol Dependence appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00218569 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00218569 about?

NCT00218569 is a clinical study titled "Combined Treatment for Cocaine-Alcohol Dependence - 1". The purpose of this study is to examine whether Naltrexone and cognitive behavioral therapy can be helpful in patients who want to stop using cocaine and alcohol.

What is the current status of trial NCT00218569?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2003-04. Estimated completion is 2007-12.

What conditions does trial NCT00218569 study?

This clinical trial studies the following conditions: Alcohol Dependence, Cocaine Dependence.

What interventions are being tested in trial NCT00218569?

The interventions under investigation include: Placebo (DRUG), Naltrexone (DRUG).

Who is sponsoring clinical trial NCT00218569?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00218569 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Dependence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00218569's enrollment target sits among peer trials

87 24th of 43 higher than 20 of 43 other Alcohol Dependence trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alcohol Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03292601 · 87 participants · NA

    Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)

  • NCT04291105 · 87 participants · Phase 2

    Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

  • NCT04565795 · 87 participants · NA

    Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy

  • NCT05607004 · 87 participants · Phase 2

    (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00218569, the US trial registry maintained by the National Library of Medicine. NCT00218569 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.